PMID- 38402348
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240427
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 14
IP  - 1
DP  - 2024 Feb 24
TI  - Biomarker screening using integrated bioinformatics for the development of 
      "normal-impaired glucose intolerance-type 2 diabetes mellitus".
PG  - 4558
LID - 10.1038/s41598-024-55199-y [doi]
LID - 4558
AB  - Type 2 diabetes mellitus (T2DM) is a progressive disease. We utilized 
      bioinformatics analysis and experimental research to identify biomarkers 
      indicative of the progression of T2DM, aiming for early detection of the disease 
      and timely clinical intervention. Integrating Mfuzz analysis with differential 
      expression analysis, we identified 76 genes associated with the progression of 
      T2DM, which were primarily enriched in signaling pathways such as apoptosis, p53 
      signaling, and necroptosis. Subsequently, using various analytical methods, 
      including machine learning, we further narrowed down the hub genes to STK17A and 
      CCT5. Based on the hub genes, we calculated the risk score for samples and 
      interestingly found that the score correlated with multiple programmed cell death 
      (PCD) pathways. Animal experiments revealed that the diabetes model exhibited 
      higher levels of MDA and LDH, with lower expression of SOD, accompanied by islet 
      cell apoptosis. In conclusion, our study suggests that during the progression of 
      diabetes, STK17A and CCT5 may contribute to the advancement of the disease by 
      regulating oxidative stress, programmed cell death pathways, and critical 
      signaling pathways such as p53 and MAPK, thereby promoting the death of islet 
      cells. This provides substantial evidence in support of further disease 
      prevention and treatment strategies.
CI  - (c) 2024. The Author(s).
FAU - Luo, Dongqiang
AU  - Luo D
AD  - Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
FAU - Gao, Xiaolu
AU  - Gao X
AD  - Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
FAU - Zhu, Xianqiong
AU  - Zhu X
AD  - Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
FAU - Xu, Jiongbo
AU  - Xu J
AD  - Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
FAU - Gao, Pengfei
AU  - Gao P
AD  - Yunkang School of Medicine and Health, Nanfang College Guangzhou, Guangzhou, 
      510000, China.
FAU - Zou, Jiayi
AU  - Zou J
AD  - Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
FAU - Fan, Qiaoming
AU  - Fan Q
AD  - Foshan Hospital of Traditional Chinese Medicine, Foshan, 528000, China.
FAU - Xu, Ying
AU  - Xu Y
AD  - Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.
FAU - Liu, Tian
AU  - Liu T
AD  - Foshan Hospital of Traditional Chinese Medicine, Foshan, 528000, China. 
      liutianfzy@163.com.
LA  - eng
GR  - grant no. 20202A011031/Guangzhou Health Science and Technology Project/
PT  - Journal Article
DEP - 20240224
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (Biomarkers)
SB  - IM
EIN - Sci Rep. 2024 Apr 25;14(1):9498. PMID: 38664473
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - *Glucose Intolerance/metabolism
MH  - Tumor Suppressor Protein p53/genetics
MH  - Biomarkers
MH  - Computational Biology
PMC - PMC10894242
OTO - NOTNLM
OT  - Bioinformatics
OT  - Developmental process
OT  - Impaired glucose tolerance
OT  - Oxidative stress
OT  - Type 2 diabetes
COIS- The authors declare no competing interests.
EDAT- 2024/02/25 00:42
MHDA- 2024/02/26 06:43
PMCR- 2024/02/24
CRDT- 2024/02/24 23:27
PHST- 2023/07/22 00:00 [received]
PHST- 2024/02/21 00:00 [accepted]
PHST- 2024/02/26 06:43 [medline]
PHST- 2024/02/25 00:42 [pubmed]
PHST- 2024/02/24 23:27 [entrez]
PHST- 2024/02/24 00:00 [pmc-release]
AID - 10.1038/s41598-024-55199-y [pii]
AID - 55199 [pii]
AID - 10.1038/s41598-024-55199-y [doi]
PST - epublish
SO  - Sci Rep. 2024 Feb 24;14(1):4558. doi: 10.1038/s41598-024-55199-y.